Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Low muscle tone (hypotonia), Hypertelorism, Feeding difficulties in infancy, and Macrocephaly and others; and very common findings: Highly arched eyebrow. 44 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Seizure, Enlarged brain ventricles (ventriculomegaly), Intellectual disability |
ASXL2 encodes ASXL transcriptional regulator 2 (1,435 aa). Putative Polycomb group (PcG) protein. Highest expression in Testis (15.2 TPM) and Cells Cultured fibroblasts (13.5 TPM).
Shashi-Pena syndrome is associated with mutations in the ASXL2 gene on chromosome 2.
ASXL2 is classified as a druggable target (Clinically Actionable, Enzyme, and Transcription Factor categories) with score 0.0.
No consensus clinical diagnostic criteria for Shashi-Pena syndrome have been published.
Shashi-Pena syndrome should be considered in individuals with the following clinical findings and family history.
Clinical findings
Source: GeneReviews — "Shashi-Pena Syndrome"
No approved treatments are currently available for Shashi-Pena syndrome. The disease remains an area of unmet medical need.
No clinical practice guidelines for Shashi-Pena syndrome have been published.
To establish the extent of disease and needs in an individual diagnosed with Shashi-Pena syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 6.
Shashi-Pena Syndrome: Recommended Surveillance
System/Concern | Evaluation | Frequency
| • Measure growth parameters.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
4 publications have been identified in PubMed for Shashi-Pena syndrome. Kisho has analyzed 3 by research type. Research spans Case Report / Case Series (67%) and Epidemiology / Natural History (33%).
Piring A (2026). [PMID: 40808361](https://pubmed.ncbi.nlm.nih.gov/40808361/). *American journal of medical genetics. Part A*. [Epidemiology / Natural History]
Al Ali A (2025). [PMID: 40759503](https://pubmed.ncbi.nlm.nih.gov/40759503/). *BMJ case reports*. [Case Report / Case Series]
Minotti C (2025). [PMID: 40475172](https://pubmed.ncbi.nlm.nih.gov/40475172/). *Molecular syndromology*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Common questions about Shashi-Pena syndrome
Bones and joints |
5 |
Weak and brittle bones (osteoporosis), Sideways curvature of the spine (scoliosis), Excessive outward curvature of the upper spine (kyphosis) |
Head and neck | 3 | Thin upper lip vermilion, Macrocephaly, Long face |
Kidneys and urinary system | 1 | Unilateral renal agenesis |
Muscles | 1 | Low muscle tone (hypotonia) |
Digestive system | 1 | Feeding difficulties in infancy |
Pregnancy and birth | 1 | Mild fetal ventriculomegaly |
Eyes | 1 | Ptosis |
Arms and legs | 1 | Limb hypertonia |
Growth and development | 1 | Intrauterine growth retardation |
Heart and blood vessels | 1 | Atrial septal defect |
Age of onset: before birth.
Shashi-Pena syndrome is characterized by distinctive facial features accompanied by variable further clinical findings, which may include macrocephaly, dental anomalies, congenital heart defects, seizures, hypoglycemia, hypotonia, developmental delays/ intellectual disabilities, skeletal abnormalities, and global volume loss on brain MRI. To date, at least 23 individuals have been identified with pathogenic truncating variants in ASXL2, including published and non-published individuals [; ; ; ; ; ; JM Porter, LDM Pena, RC Spillmann, A Johnson, V Shashi, unpublished data]. The following description of the phenotypic features associated with this condition is based on these individuals. Table 2. Shashi-Pena Syndrome: Frequency of Select Features1,2
Feature | Number of Persons w/Feature | Comment |
|---|---|---|
Glabellar nevus simplex | 23/23 (100%) | — |
Distinctive facial features | 22/22 (100%) | See . |
Dental abnormalities | 14/14 (100%) | Early eruption loss; small, fragile teeth |
Developmental delay/intellectual disability | 20/21 (95%) | Variable, ranging from low-average intellectual abilities to severe intellectual disabilities |
Hypotonia | 19/20 (95%) | Gradual improvement w/age; likely to be central |
Other skin findings | 17/20 (85%) | Capillary malformations (11/20), deep palmar creases (6/20), hypertrichosis (4/20) |
Feeding difficulties (newborn) | 17/20 (85%) | May require nasogastric/gastrostomy tube feeding, but usually resolve over time |
Feeding difficulties (childhood) | 5/18 (28%) | — |
Skeletal anomalies | 14/17 (82%) | May incl scoliosis/kyphosis, hypermobility, /or frequent fractures |
Congenital heart defects | 17/21 (81%) | ASD, PFO, PDA |
Macrocephaly | 15/20 (75%) | Congenital acquired both reported |
Vision abnormalities | 11/15 (73%) | Strabismus, amblyopia; ptosis is part of the distinctive facial features |
Behavior problems | 10/14 (71%) | Aggression, anger outbursts |
Seizures | 12/18 (67%) | Febrile /or non-febrile |
Hypoglycemia | 13/20 (65%) | Most often in neonates may be due to hyperinsulinism; frequently resolves over time |
Macrosomia | 10/18 (55%) | — |
Hearing loss | 7/15 (47%) | Typically conductive |
Sleep apnea | 7/15 (47%) | May be obstructive or mixed central/obstructive |
Temperature dysregulation | 6/14 (43%) | ASD = atrial septal defect; PFO = patent foramen ovale; PDA = patent ductus arteriosus Data is derived from 12 published individuals and 11 unpublished individuals [; ; ; ; ; ; JM Porter, LDM Pena, RC Spillmann, A Johnson, V Shashi, unpublished data]. 2. Skin. |
Source: GeneReviews — "Shashi-Pena Syndrome"
Table 3.
Genes of Interest in the Differential Diagnosis of Shashi-Pena Syndrome
Gene/ Genetic Mechanism | Disorder | MOI | Clinical Features of Disorder
Overlapping w/Shashi-Pena syndrome | Distinguishing from Shashi-Pena syndrome
| Bohring-Opitz syndrome | AD | • Glabellar nevus simplex
Hypertelorism, prominent eyes
Hypertrichosis
Seizures
| • Poor postnatal weight gain linear growth
Microcephaly
More severe feeding difficulties incl cyclic vomiting
High myopia
BOS posture1
Severe-to profound-ID
| ASXL3-related disorder (Bainbridge-Ropers syndrome) | AD | • DD
Hypotonia
Feeding difficulties
Epilepsy
| • Marfanoid habitus
Pectus excavatum
Joint flexion w/contractures
Abnormal methylation at 11p15.5; CDKN1C2 | Beckwith-Wiedemann syndrome | See footnote 2. | • Macrosomia
Source: GeneReviews — "Shashi-Pena Syndrome"
Genetic testing for ASXL2 is available. Testing is considered confirmatory for diagnosis.
Shashi-Pena Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Measurement of growth parameters, incl head circumference | To assess for macrocephaly overgrowth
| Dental eval | Typically for those age 3 yrs at time of diagnosis
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education
Neurobehavioral/
| Neurobehavioral screening assessment | For persons age 12 mos: screening for concerns incl difficulties w/attention, anger outbursts, aggression. Screening may follow the AAP guidelines to include M-CHAT-R/FTM and other instruments to assess for autistic features.
| Neurologic eval | • Consider brain MRI for rapidly head circumference or focal seizures.
Consider EEG if seizures are a concern.
Incl assessment for temperature dysregulation.
Gastrointestinal/
| Gastroenterology/ nutrition/ feeding team eval | • To incl eval of aspiration risk nutritional status
Consider eval for gastrostomy tube placement in those w/feeding difficulties.
| Orthopedics/ physical me...
Source: GeneReviews — "Shashi-Pena Syndrome"
Prolonged fasting should be avoided in those with hypoglycemia.
Source: GeneReviews — "Shashi-Pena Syndrome"
1 trial found
Evaluate nutritional status safety of oral intake.
| At each visit
| Monitor developmental progress educational needs.
| • Monitor for difficulties w/attention, anger outbursts, aggression.
Monitor for signs of ADHD, autism spectrum disorder, anxiety.
| • Monitor those w/seizures as clinically indicated.
Assess for new manifestations such as seizures changes in tone.
Monitor for signs/symptoms of temperature dysregulation.
| Monitor for signs/symptoms of sleep apnea.
| Monitor for signs of feeding difficulty.
| • Physical medicine, OT/PT assessment of mobility, self-help skills
Clinical exam for scoliosis/kyphosis
Spine radiographs | As clinically indicated
DXA scan
| Dental /or orthodontic eval | As clinically indicated for those w/more significant dental issues
Eyes | Ophthalmology eval | Annually or as clinically indicated
| • Assess for signs/symptoms of hypoglycemia.
Monitor educate caregivers re symptoms of hypoglycemia or hyperglycemia.
| At each visit
Blood glucose monitoring | As clinically indicated
| Audiology eval
| Assess family need for social work suppor...
Source: GeneReviews — "Shashi-Pena Syndrome"
Phenotype severity distribution: 6 always present features, 1 very common feature, 18 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).